Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

4765 - Randomized, Phase II Study of Ficlatuzumab with or without Cetuximab in Patients (pts) with Cetuximab-Resistant, Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Topics

Tumour Site

Head and Neck Cancers

Presenters

Julie Bauman

Citation

Annals of Oncology (2018) 29 (suppl_8): viii372-viii399. 10.1093/annonc/mdy287

Authors

J.E. Bauman

Author affiliations

  • Medicine, University of Arizona Cancer Center, 85724-5024 - Tucson/US
More

Resources

Abstract 4765

Background

Cetuximab, an anti-EGFR monoclonal antibody (mAb), is approved for R/M HNSCC but only a minority benefits. c-Met and EGFR signaling converge at the PI3K/Akt and MAPK nodes. Preclinical evidence shows that c-Met can drive tumor-intrinsic resistance to EGFR inhibition. Ficlatuzumab is an IgG1 mAb against HGF, the sole ligand for cMet. We recently completed a phase Ib study evaluating ficlatuzumab and cetuximab in pts with cetuximab-resistant, R/M HNSCC (Bauman JE et al, ASCO 2017). Twelve pts were treated; 11 were platinum-refractory. Grade 3 adverse events included edema, hypoalbuminemia, infection, and thromboembolism. No DLTs were seen. Median progression-free survival (PFS) at the recommended phase II dose (RP2D) was 6.0 mos (90% CI = 2 mos – not reached). Confirmed overall response rate (ORR) was 17% (90% CI = 0-28%). Clinical benefit rate was 67%. Serum Veristrat, a proteomic classifier predictive of differential treatment benefit from anti-EGFR therapy, did not correlate with PFS. We designed a randomized phase II trial evaluating ficlatuzumab with or without cetuximab in patients with cetuximab-resistant, R/M HNSCC. The combination arm follows the hypothesis that continued anti-EGFR blockade may overcome reciprocal compensation between the EGFR and cMet pathways.

Trial design

This is a multicenter phase II trial with a randomized, non-comparative, 2-arm design (Arm A: ficlatuzumab and Arm B: ficlatuzumab + cetuximab) in pts with R/M HNSCC after failure of cetuximab. Key eligibility criteria include: R/M HNSCC; cetuximab resistance (recurrence during or within 6 mos of cetuximab-radiation or palliative cetuximab); ECOG 0-1; mandatory baseline research biopsy. The primary objective is to assess the efficacy of ficlatuzumab, with or without cetuximab, as measured by PFS. To test the hypothesis that either regimen improves historical PFS from 2 months to 3.33 months requires 66 eligible patients. Key secondary endpoints are ORR and survival. Biomarkers to be correlated with efficacy include tumor HGF/cMet dimers, phosphoproteins, and immunoscores and serum Veristrat. Two of 66 patients have enrolled.

Clinical trial identification

Legal entity responsible for the study

University of Arizona Cancer Center.

Funding

University of Arizona Cancer Center; Aveo.

Editorial Acknowledgement

Disclosure

The author has declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.